Datapoint: AbbVie Scores New Migraine Nod for Qulipta

The FDA on April 17 approved AbbVie’s Qulipta for the prevention of chronic migraine, making it the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to treat both episodic and chronic migraine headaches. The drug was first approved in 2021 for the prevention of episodic migraines, an indication for which it currently holds covered or better status for 77% of all insured lives under the pharmacy benefit. AbbVie in its press release touted itself as the only drugmaker with therapies that cover the “full spectrum” of migraine treatment and prevention — its Botox was the first FDA-approved chronic migraine prevention treatment, while its Ubrelvy treats acute migraine attacks.

SOURCE: MMIT Analytics, as of 4/19/23

0

0

0 Comments

0

0

• Datapoint